GlassScriptPhysician profile
Velupillai Wignakumar
NPI 1265495063
$12,568.91
in general payments reported to CMS, 2019-2025
12 companies · $11.52 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $673 · 2021: $53.84 · 2022: $9,812 · 2023: $589 · 2024: $15.42 · 2025: $11.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Travel and Lodging: $181 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.54 |
| Travel and Lodging | $180.50 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,498.07 | 2022-2023 | Da Vinci Surgical System |
| Bard Peripheral Vascular, INC. | $1,639.80 | 2019-2020 | |
| Globus Medical, INC. | $903.43 | 2022 | |
| W. L. Gore & Associates, INC. | $389.02 | 2020 | |
| Davol INC. | $41.34 | 2021 | |
| Amarin Pharma, INC. | $16.89 | 2019 | |
| Smith+Nephew, INC. | $15.42 | 2024 | Collagenase Santyl |
| Genentech USA, INC. | $14.99 | 2020 | |
| Boston Scientific Corporation | $13.30 | 2019 | |
| Radius Health, INC. | $12.63 | 2019 | |
| Daiichi Sankyo INC. | $12.50 | 2021 | |
| Reprise Biomedical, INC. | $11.52 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Velupillai Wignakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.